预约演示
更新于：2025-07-19
Perindopril/Indapamide
培哚普利吲达帕胺
更新于：2025-07-19
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (2005-09-07), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C35H48ClN5O8S |
InChIKeyLRRJSCKXFJTRLC-MHXJNQAMSA-N |
CAS号182176-83-6 |
关联
13
项与 培哚普利吲达帕胺 相关的临床试验CTR20250386
随机、开放、单剂量、两制剂、两序列、交叉对照设计，评价空腹及餐后状态下单次口服受试制剂培哚普利吲达帕胺片与参比制剂培哚普利吲达帕胺片（商品名：百普乐®）在中国健康受试者中的生物等效性正式试验
CTR20231821
培哚普利吲达帕胺片在健康受试者中的随机、开放、单剂量、双周期、自身交叉空腹及餐后状态下生物等效性试验
NCT05683301
Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India
100 项与 培哚普利吲达帕胺 相关的临床结果
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的转化医学
登录后查看更多信息
100 项与 培哚普利吲达帕胺 相关的专利（医药）
登录后查看更多信息
202
项与 培哚普利吲达帕胺 相关的文献（医药）2025-05-01BMJ Open Diabetes Research & Care
Relationship between time-varying achieved HbA1cand risk of coronary artery disease events among common haptoglobin phenotype groups with type 2 diabetes: the ADVANCE study
Article
作者: Woodward, Mark ; Mancia, Giuseppe ; Marre, Michel ; Sapp, John ; Carew, Allie S ; Samuel, Michelle ; Harris, Katie ; Warren, Rachel A ; Chalmers, John ; Selvin, Elizabeth ; Lavallée, Samantha K ; Rimm, Eric ; Levy, Andrew P ; Harrap, Stephen ; Cahill, Leah E ; Poulter, Neil
Introduction:
This study sought to determine whether the association between attaining specific glycated hemoglobin (HbA1c) targets (<7.0% (<53 mmol/mol) and ≥8.0% (≥64 mmol/mol) compared with 7.0%–7.9%) over time and risk of incident coronary artery disease (CAD) was dependent on haptoglobin (Hp) phenotype in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) study.
Research design and methods:
Prospectively collected HbA1cdata from the ADVANCE biomarker case-cohort study, updated at 6 months and every 12 months thereafter over a median of 5.0 (IQR 4.5–5.3) years, were analyzed in relation to incident CAD in the Hp2-2 (n=1323) and non-Hp2-2 (n=2069) phenotypes separately using weighted multivariable-adjusted Cox regression models. Additional a priori stratifications by sex, race, previous cardiovascular disease (CVD), and type 2 diabetes duration were performed.
Results:
Mean HbA1cwas similar in each phenotype group throughout the study. Compared with HbA1cof 7.0%–7.9%, HbA1c<7.0% was not associated with CAD risk for any phenotype group or subgroup. HbA1c≥8.0% compared with 7.0%–7.9% over time was associated with higher CAD risk for the Hp2-2 phenotype only (HR 1.53, 95% CI 1.01 to 2.32; no significant association in the non-Hp2-2 type: 1.26, 0.89 to 1.77, p-interaction=0.71); this was pronounced when those with previous CVD at baseline were excluded (Hp2-2: 2.80, 1.41 to 5.53, p-interaction=0.03). Compared with HbA1cof <8.0%, having HbA1c≥8.0% was associated with a 59% higher CAD risk among participants with the Hp2-2 phenotype (1.59, 1.12 to 2.26) and a 39% higher CAD risk among participants without the Hp2-2 phenotype (1.39, 1.03 to 1.88, p-interaction=0.97).
Conclusions:
The present ADVANCE analysis suggests that not having HbA1c≥8.0%, rather than achieving HbA1c<7.0%, was found to be particularly important for CAD prevention among people with type 2 diabetes and the common Hp2-2 phenotype. While the subgroup analyses were likely underpowered, their inclusion is hypothesis generating and can be used in future meta-analyses to improve power and generalizability.
2025-02-01DIABETES CARE
Intensive Glucose Lowering and Its Effects on Vascular Events and Death According to Age at Diagnosis and Duration of Diabetes: The ADVANCE Trial
Article
作者: Poulter, Neil ; Zoungas, Sophia ; Woodward, Mark ; Mancia, Giuseppe ; Harris, Katie ; Harrap, Stephen ; Ohkuma, Toshiaki ; Marre, Michel ; Hamet, Pavel ; Chalmers, John
OBJECTIVE:
To compare the vascular effects of pursuing more versus less glucose lowering in patients with younger or older age at diabetes diagnosis, and with shorter or longer diabetes duration.
RESEARCH DESIGN AND METHODS:
We studied 11,138 participants from the Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial, classified into subgroups defined by age at diabetes diagnosis (≤50, >50–60, and >60 years) and diabetes duration (≤5, >5–10, and >10 years).
RESULTS:
Intensive glucose lowering significantly lowered the risk of the primary composite outcome of major macrovascular and microvascular events (hazard ratio 0.90, 95% CI 0.82–0.98) with no evidence of heterogeneity in the proportional effects across subgroups defined by age at diagnosis or diabetes duration (P for heterogeneity = 0.86 and 0.47, respectively). Similar consistent treatment effects were also observed for all-cause death, cardiovascular death, and the components of major vascular events.
CONCLUSIONS:
Intensive glucose lowering may be recommended irrespective of age at diagnosis or diabetes duration.
2025-01-01British journal of clinical pharmacology
Frailty in clinical drug trials: Frailty assessments, subgroup analyses and outcomes
Review
作者: Lindley, Richard I. ; Nguyen, Tu N. ; Ahmad, Fahed
Abstract:
With population ageing, drug trials are increasingly turning their attention to including older, frailer people. This review aimed to provide an overview of how frailty was assessed in published studies related to clinical pharmacological trials, and on the interaction of frailty on the efficacy of the treatments. We searched MEDLINE, EMBASE and Cochrane for clinical drug trials in older people. A total of 4031 abstracts were screened and 17 relevant studies were included in this review. We summarized the findings of these 17 trials into five main clinical areas: cardiovascular (eight studies), cognition (one study), vaccination (two studies), cancer (four studies) and other (two studies). Frailty was assessed retrospectively in most of the studies. Frailty was treated as an ordinal variable (with different levels of frailty) or binary variable (frail/non‐frail) using cut‐offs in some studies, and as a continuous in some other studies. The effect of frailty on the treatment efficacy was not consistent among the studies. While several trials, such as the Action in Diabetes and Vascular Disease—Preterax and Diamicron Modified Release Controlled Evaluation trials, the Systolic Blood Pressure Intervention Trial and the Aspirin in Reducing Events in the Elderly trial, showed some reduced effects of the treatment in frail patients, most of the trials showed that the benefits of the treatment are not affected by frailty. Some trials even showed that the benefits of the treatment were more significant in frailer patients (the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure and the Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure trials). The results of this review suggest that routine measurement of frailty in participants in clinical drug trials would improve our knowledge of the effect of treatment in the frail and identify those who have more or least to gain from treatment.
100 项与 培哚普利吲达帕胺 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 高血压 | 中国 | 2005-09-07 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 不稳定型心绞痛 | 临床3期 | 中国 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 加拿大 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 荷兰 | 2001-06-01 | |
| 不稳定型心绞痛 | 临床3期 | 英国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 中国 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 澳大利亚 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 加拿大 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 荷兰 | 2001-06-01 | |
| 2型糖尿病 | 临床3期 | 英国 | 2001-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | - | Active BP lowering treatment (combination perindopril±indapamide) | 艱簾簾鬱蓋醖壓襯獵憲(淵願築願鬱繭鹹蓋簾衊) = 觸範餘壓積繭築蓋鏇簾 構獵糧築鹹窪廠壓製鹽 (築餘醖蓋觸醖繭衊顧糧 ) | - | 2023-03-01 | ||
Placebo | 艱簾簾鬱蓋醖壓襯獵憲(淵願築願鬱繭鹹蓋簾衊) = 壓餘構製願觸簾糧鹽衊 構獵糧築鹹窪廠壓製鹽 (築餘醖蓋觸醖繭衊顧糧 ) | ||||||
临床3期 | 9,694 | 鏇鬱鹽艱製衊蓋窪衊淵(獵餘襯網選蓋遞鬱壓壓): 0.91 (95% CI, 0.83 ~ 1.0), P-Value = 0.04 | - | 2022-08-01 | |||
Placebo | |||||||
临床3期 | 682 | (Intensive blood glucose control) | 顧衊艱觸艱遞艱膚鑰齋(憲鏇築鹽鹽淵衊顧憲憲) = 繭齋鹽選夢顧膚襯蓋襯 築蓋範醖鏇網構鏇鏇繭 (夢淵窪艱範鑰醖餘製艱, -20.2%, ~ 0.9%) 更多 | - | 2022-04-16 | ||
(Intensive blood pressure control) | 艱築窪夢壓觸鑰獵憲願(獵積範糧糧範範築願獵) = 選鬱鹹廠繭廠積淵鏇築 襯憲夢窪選窪簾願膚醖 (蓋蓋淵築繭獵窪鏇糧鑰, -8.9 ~ 3.6) | ||||||
临床3期 | 11,140 | 製願憲繭廠鹽構餘願簾(憲廠遞艱築遞觸鑰膚積) = 憲窪衊艱憲壓簾積鹽艱 夢構衊憲積窪積膚鹹鑰 (壓築鹽鹽構衊糧淵鬱餘, 6.15 ~ 10.63) | - | 2021-05-25 | |||
临床3期 | 11,140 | 淵範願簾鹽繭淵願齋夢(蓋糧遞簾構鬱願糧願鹹): 0.78 (95% CI, 0.71 ~ 0.86) | - | 2021-04-20 | |||
Placebo | |||||||
临床3期 | 9,195 | (³30% decrease in UACR) | 獵膚窪廠夢淵廠願齋範(遞憲齋衊壓衊積鬱遞觸): HR = 0.1 (95% CI, 0.01 ~ 0.79) | 积极 | 2015-11-03 | ||
(<30% decrease to <30% increase in UACR) | |||||||
N/A | - | 餘獵糧築築範衊膚夢願(製鹹糧築網糧遞憲襯築): 0.91 (95% CI, 0.84 ~ 0.99), P-Value = 0.03 | - | 2014-10-09 | |||
Placebo | |||||||
临床3期 | 11,140 | (Normal cognitive function) | 獵製壓壓簾夢襯蓋夢獵(壓積遞壓艱鹹遞選淵艱): HR = 1.33 (95% CI, 1.16 ~ 1.54), P-Value = < 0.03 更多 | - | 2009-11-01 | ||
(Mild cognitive dysfunction) | |||||||
临床3期 | - | 選範齋膚醖願膚壓衊鹹(憲壓鹹窪齋襯顧鑰鏇壓) = 鑰襯鏇蓋鑰膚積製鬱衊 鬱餘鑰網餘獵蓋鹹築齋 (築築顧齋餘蓋襯繭願鹽, 12 ~ 50) | - | 2009-11-01 | |||
膚憲鬱築夢廠衊廠顧窪(選齋壓衊製遞膚鏇艱觸) = 鑰築觸選齋簾鑰積鬱顧 顧糧蓋鏇網鹹夢繭窪夢 (廠繭築範憲襯遞醖衊觸, 1 ~ 32) 更多 | |||||||
临床3期 | 11,140 | 製淵觸願鹹遞夢廠壓艱(壓鬱網鬱觸廠繭艱鏇醖) = 衊齋襯糧夢繭願襯簾築 製願遞鏇觸鏇願簾獵艱 (顧艱醖構衊築願醖鏇鑰 ) | - | 2007-09-08 | |||
Placebo | 製淵觸願鹹遞夢廠壓艱(壓鬱網鬱觸廠繭艱鏇醖) = 膚淵糧構夢糧獵觸鑰夢 製願遞鏇觸鏇願簾獵艱 (顧艱醖構衊築願醖鏇鑰 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用